

A Novel Convergent Strategy for the Construction of Oligosaccharides Using TIPS-Protected Glycosides. Synthesis of Fragments Related to Glycolipids of *Mycobacterium smegmatis*

Thomas Ziegler*, and Elisabeth Eckhardt

Institut für Organische Chemie und Isotopenforschung, Universität Stuttgart, Pfaffenwaldring 55, 7000 Stuttgart 80.

Abstract: 4,6-*O*-Pyruvylated glucosides **1** were converted to the corresponding glucosyl fluorides **3** and 2,3-*O*-TIPS-protected glucopyranosides **5**, respectively. Lewis-acid-catalyzed coupling of **3** and **5** afforded the pyruvylated disaccharides **6** one of which was further converted via the disaccharide donor **8** to di- and trisaccharide fragments of *Mycobacterium smegmatis*.

Otherwise apathogenic *Mycobacteria* can cause severe infections (atypical mycobacterioses) in immuno compromised persons especially in those suffering from AIDS¹. The diagnosis of atypical mycobacterioses is however difficult in an early stage of infection due to the need to identify the bacteria via cultivation. Furthermore, some atypical *Mycobacteria* are ubiquitous environmental germs, for example *Mycobacterium smegmatis* and can thus lead to contamination and false interpretation of the cultivation. Therefore, the development of highly specific diagnostic tools for these atypical infections is quite important, also in order to be able to differentiate unambiguously between distinct mycobacterial diseases. A recent promising approach employed species specific neoglycoantigens² and synthetic oligosaccharides³ of *Mycobacteria* for that purpose. Thus, effective syntheses of *Mycobacterium*-related saccharides are highly desirable and novel convenient strategies for their preparation would help to improve significantly further developments.

Recently, we found that TIPS-protected glycosides were regioselectively glycosylated by glycosyl fluorides under Lewis-acid-catalysis⁴. Using glycosyl fluorides having a neighboring group active acyl substituent at position 2 β -(1 \rightarrow 6)-linked saccharides were obtained from 4,6-*O*-TIPS-protected glycosides. Contrarily, from 3,4-*O*- and 2,3-*O*-TIPS-protected glucosides β -(1 \rightarrow 3)-linked saccharides were obtained exclusively. Here, we now used the latter β -(1 \rightarrow 3)-selective glycosylation protocol for a novel convergent strategy for the synthesis of the complex pyruvylated oligosaccharide fragments AB and ABC of the lipopentasaccharide⁵ from *Mycobacterium smegmatis* (Figure 1).





Figure 1. Structure of the lipopentasaccharide isolated from *Mycobacterium smegmatis*⁵. Fatty acid residues: FA (D) = 2,4-dimethyl-2-eicosenoic acyl; FA (E) = tetra- or hexadecanoic acyl. The pyruvate acetals of residues A and B have the (*S*)-configuration as can be concluded from the proton NMR spectra.

Starting from the readily prepared benzyl 2,3-di-*O*-benzoyl-4,6-*O*-(*S*)-(1-methoxycarbonyl)ethylidene- α -D-glucopyranoside⁶ (1a) and its 3-*O*-methyl analogue⁶ 1b Pd-catalyzed hydrogenolysis gave the 1-*O*-unprotected glucoses 2a⁶ and 2b in a practically quantitative yield. The latter two compounds were subsequently converted⁷ (1.1 equiv. DAST in THF, -30°C \rightarrow room temp., 1h) to the fluorides 3a (76%) and 3b (73%), respectively. The fluoride 3a was obtained as crystalline β -anomer, whereas amorphous 3b contained a small amount of the α -fluoride, according to the NMR spectra⁸, that could not be removed by chromatography. On the other hand, compound 1a was debenzoylated (Zémlen: cat. NaOMe in MeOH, room temp., 24h), to give the derivative 4 (85%) having positions 2 and 3 free. Upon silylation⁴ (1.2 equiv. TIPSCl₂, 4.8 equiv. imidazole, DMF, room temp., 1h) the diol 4 furnished benzyl 4,6-*O*-(*S*)-(1-methoxycarbonyl)ethylidene-2,3-*O*-(1,1,3,3-tetraisopropyl-disiloxane-1,3-diyl)- α -D-glucopyranoside (5) in 77% yield (Scheme 1).

Scheme 1. Synthesis of the laminaribioside derivatives 6 from pyruvylated benzyl glucosides 1.




BF₃-etherate-catalyzed glycosylation of compound 5 (50 mol-% BF₃OEt₂, CH₂Cl₂) with 3a (room temp., 24h) and 3b (0°C \rightarrow room temp., 48h), respectively proceeded smoothly and afforded first the corresponding addition products that still contained the fluorinated TIPS residue (3-fluoro-1,1,3,3-tetraisopropyl-disiloxane-1-yl) at position 2¹ of the disaccharides. A small amount of already desilylated disaccharide could be detected on TLC as was previously described for other examples⁴. Therefore, the latter intermediates were not isolated and characterized here but were directly desilylated in a one-pot-procedure (cat. Bu₄NF \cdot 3H₂O, THF, room temp. 1h), followed by rebenzoylation (BzCl, pyridine, room temp. 1-2h) of thus formed 2¹-OH compounds. Finally, the pyruvylated disaccharides 6a (50%) and 6b (81%) were obtained (Scheme 1). Their NMR spectra⁸ clearly showed the presence of a β -(1 \rightarrow 3)-linkage. The above outlined one-pot-

procedure had the advantage that the somehow difficult isolation of the apolar silylated intermediates was circumvented and the fully benzoylated products **6** could be easily separated from contaminant byproducts by simple chromatography. The achieved moderate to good yields of this method and the convenient isolation of compounds **6** justified to proceed this way. The glycosylation protocol presented here should be also suitable for other oligosaccharide syntheses and further extensions of the method are now under investigation.

Compounds **6** are useful intermediates for the construction of higher oligosaccharides related to *Mycobacterium smegmatis* that contain two adjacent pyruvylated glucose residues (Scheme 2). For example, the benzyl laminaribioside **6b** was transformed to the complex disaccharide donor **8** via hydrogenolysis (10 % Pd-C, H₂, HOAc, room temp., 3d) to give first crude **7**. Without further purification, the latter was treated with trichloroacetonitrile (Cl₃CCN, K₂CO₃, CH₂Cl₂, room temp., 5h) to give the trichloroacetimidate **8** (90%) as an anomeric mixture ($\alpha:\beta=1:1.4$)⁸. TMSOTf-catalyzed condensation (1 mol-% TMSOTf, CH₂Cl₂, -20°C, 1h) of donor **8** and 5-benzoyloxycarbonylamido pentanol was somehow sluggish and the resulting aminopentyl laminaribioside had to be partially deblocked (Zémpfen) in order to obtain pure **9** (59%). The deblocking of the latter was then achieved by saponification of the two acetal-bound methyl pyruvates (4 equiv. 1 N NaOH, H₂O, room temp., 24h) and hydrogenolytic debenzoylation (cat. 10% Pd-C, H₂, H₂O, room temp. 12h) to afford the AB-fragment **10** (46%).

Scheme 2. Synthesis of the mycobacterial fragments AB and ABC from the laminaribiose derivative **6b**.



Condensation of donor **8** and methyl 2,3,6-tri-*O*-benzyl- β -D-glucopyranoside **11** as described above proceeded smoothly and gave the trisaccharide **12** in 79% yield. The deblocking of **12** was then performed by first removing the benzoyl groups (Zémpfen) followed by saponification and hydrogenolysis as described for **10**, to furnish the ABC-fragment **13** in 98% yield.

Acknowledgment

We thank Prof. Dr. Dr. h.c. F. Effenberger for helpful discussions and for providing the working facilities. This work was financially supported by the Deutsche Forschungsgemeinschaft.

References and Notes

1. P. Zakowski, S. Fligiel, G. W. Berlin, B. L. Johnson, *J. Amer. Med. Assoc.*, **1982**, *248*, 2920-2982; J. M. Wallace, J. B. Hannah, *Chest*, **1988**, *93*, 926-932; M. McNeil, D. Chatterjee, S. W. Hunter, P. J. Brennan, *Meth. Enzymol.*, **1989**, *179*, 215-242.
2. B. Rivoire, B. J. Ranchoff, D. Chatterjee, H. Gaylord, A. Y. Tsang, A. H. J. Kolk, G. O. Aspinall, P. J. Brennan, *Infect. Immun.*, **1989**, *57*, 3147-3158; W. R. Thayer, C. M. Bozic, R. T. Camphausen, M. McNeil, *J. Clin. Microbiol.*, **1990**, *28*, 714-718; G. O. Aspinall, A. M. Crane, D. W. Gammon, I. H. Ibrahim, N. K. Khare, D. Chatterjee, B. Rivoire, P. J. Brennan, *Carbohydr. Res.*, **1991**, *216*, 337-355.
3. Z. Szurmai, J. Kerékgyártó, J. Harangi, A. Lipták, *Carbohydr. Res.*, **1987**, *164*, 313-325; A. Lipták, J. Kerékgyártó, Z. Szurmai, *Carbohydr. Res.*, **1988**, *175*, 241-248; M. K. Gurjar, G. Viswanadham, *Tetrahedron Lett.*, **1991**, *32*, 6191-6194.
4. T. Ziegler, K. Neumann, E. Eckhardt, G. Herold, G. Pantkowski, *Synlett*, **1991**, 699-701.
5. S. Saadat, C. E. Ballou, *J. Biol. Chem.*, **1983**, *258*, 1813-1818; K.-i. Kamisango, S. Saadat, A. Dell, C. E. Ballou, *J. Biol. Chem.*, **1985**, *260*, 4117-4121.
6. T. Ziegler, E. Eckhardt, G. Herold, *Liebigs Ann. Chem.*, **1992**, 441-451; T. Ziegler, E. Eckhardt, G. Herold, *Tetrahedron Lett.*, **1992**, in press; T. Ziegler, E. Eckhardt, K. Neumann, V. Birault, *Synthesis*, **1992**, in press.
7. G. Posner, S. R. Haines, *Tetrahedron Lett.*, **1985**, *26*, 5-8.
8. Physical data of compounds 2-13. All compounds gave satisfactory elemental analyses; NMR spectra and opt. rot. were measured in chloroform: 2b: m.p. 164-168°C; $[\alpha]_D^{20} = +88.5$ (c 0.7); NMR $\delta = 5.50$ (bd, 1H, H-1 α , J=3.7), 4.80 (bd, 1H, H-1 β , J=8.3), 3.80 (s, 3H, COOMe), 3.50 (s, 3H, OMe), 1.55 (s, 3H, Me); 99.1 (C α), 91.1 (C-1 α), 96.3 (C-1 β), 61.9, 60.0 (OMe), 25.5 (Me). 3a: m.p. 160-161°C, $[\alpha]_D^{20} = -76.7$ (c 0.3); NMR $\delta = 5.60$ (dd, 1H, H-1, J $_{H,F} = 51.7$, J $_{1,2} = 5.4$), 3.84 (s, 3H, COOMe), 1.52 (s, 3H, Me); 106.3 (C-1, J $_{C,F} = 220$), 99.6 (C α), 73.8 (C-4,5), 72.2 (C-2, J $_{C,F} = 30$), 71.9 (C-3, J $_{C,F} = 6$), 65.3 (C-6), 52.8 (COOMe), 25.2 (Me). 3b (β -anomer): NMR $\delta = 5.73$ (dd, 1H, H-1, J $_{H,F} = 50.8$, J $_{1,2} = 5.4$), 3.87 (s, 3H, COOMe), 3.49 (s, 3H, OMe), 1.57 (s, 3H, Me); 106.2 (C-1, J $_{C,F} = 221$), 80.1 (C-3), 75.7 (C-4,5), 72.0 (C-2, J $_{C,F} = 23$), 65.1 (C-6), 58.7 (OMe), 52.9 (COOMe), 25.4 (Me). 4: $[\alpha]_D^{20} = +83.8$ (c 0.2); NMR $\delta = 4.94$ (d, 1H, H-1, J $_{1,2} = 3.9$), 4.73, 4.53 (2d, 2H, CH $_2$ Ph, J=11.8), 3.96 (dd, 1H, H-6a, J $_{6a,6b} = 9.7$), 3.87 (t, 1H, H-4, J $_{3,4} = 9.3$, J $_{4,5} = 9.6$), 3.71 (dd, 1H, H-6b, J $_{5,6} = 9.7$), 3.62-3.66 (m, 1H, H-5), 3.57 (dd, 1H, H-2, J $_{2,3} = 9.3$), 3.31 (t, 1H, H-3), 3.82 (s, 3H, COOMe), 1.55 (s, 3H, Me); 99.2 (C-1), 98.1 (C α), 76.8 (C-4), 72.8, 71.5 (C-2,3), 70.0 (CH $_2$ Ph), 65.2 (C-6), 62.2 (C-5), 52.9 (COOMe), 25.3 (Me). 5: $[\alpha]_D^{20} = 70.1$ (c 4.3); NMR $\delta = 4.84$ (d, 1H, H-1, J $_{1,2} = 3.8$), 4.76, 4.59 (d, 2H, CH $_2$ Ph, J=12.7), 4.03 (dd, 1H, H-6a, J $_{5,6a} = 4.6$, J $_{6a,6b} = 9.6$), 4.03 (t, 1H, H-4, J $_{3,4} = 9.4$, J $_{4,5} = 9.5$), 3.78 (dd, 1H, H-5), 3.79 (s, 3H, COOMe), 3.74 (dd, 1H, H-6b), 3.73 (dd, 1H, H-2, J $_{2,3} = 8.5$), 3.23 (t, 1H, H-3), 1.51 (s, 3H, Me), 1.02-1.09 (m, 16H, TIPS); 99.1 (C α), 98.6 (C-1), 77.6 (C-4), 75.7 (C-2), 73.0 (C-3), 69.3 (CH $_2$ Ph), 65.7 (C-6), 61.9 (C-5), 52.4 (COOMe), 25.3 (Me). 6a: $[\alpha]_D^{20} = +106.7$ (c 0.3); NMR $\delta = 5.53$ (dd, 1H, H-2 1 , J $_{1,2} = 7.5$, J $_{2,3} = 9.1$), 5.18 (d, 1H, H-1 2), 5.08 (d, 1H, H-1 1 , J $_{1,2} = 3.8$), 4.95 (dd, 1H, H-2 1 , J $_{2,3} = 9.9$), 4.64, 4.41 (d, 2H, CH $_2$ Ph, J=12.3), 3.77, 3.87 (s, 6H, COOMe), 1.48, 1.44 (s, 6H, Me); 99.7 (C-1 2), 99.3, 99.2 (C α), 95.8 (C-1 1), 74.8, 74.7, 74.5, 73.3, 72.6, 72.4 (C-2 1 , 3 1 , 4 1 , 2 2 , 3 2 , 5 2), 69.8 (CH $_2$ Ph), 66.2 (C-4 2), 65.2 (C-6 1 , 6 2), 62.4 (C-5 1), 52.8, 52.7 (COOMe), 25.2, 25.1 (Me). 6b: $[\alpha]_D^{20} = +70.7$ (c 0.9); NMR $\delta = 5.16$ (d, 1H, H-1 2 , J $_{1,2} = 7.5$), 5.09 (d, 1H, H-1 1 , J $_{1,2} = 3.9$), 4.63, 4.40 (d, 2H, CH $_2$ Ph, J=12.2), 3.86, 3.82 (s, 6H, COOMe), 3.41 (s, 3H, OMe), 1.55, 1.46 (s, 6H, Me); 99.8 (C-1 2), 99.2, 99.1 (C α), 95.8 (C-1 1), 80.4 (C-3 2), 77.2 (C-3 1), 75.9 (C-4 2), 74.6 (C-4 1), 73.7, 72.8 (C-2 1 , 2 2), 69.9 (CH $_2$ Ph), 65.8, 62.4 (C-5 1 , 5 2), 65.2 (C-6 1 , 6 2), 58.1 (OMe), 52.8 (COOMe), 25.5, 25.1 (Me). 8 ($\alpha:\beta = 1:1.4$): $[\alpha]_D^{20} = +35.9$ (c 0.4); NMR $\delta = 6.48$ (d, 1H, H-1 $^1\alpha$, J $_{1,2} = 3.8$), 5.98 (d, 1H, H-1 $^1\beta$, J $_{1,2} = 6.0$), 5.20 (d, 1H, H-1 2 , J $_{1,2} = 7.6$), 93.6 (C-1 $^1\alpha$), 95.6 (C-1 $^1\beta$), 99.1 (C-1 2), 99.4, 99.1 (C α), 58.2 (OMe), 53.0, 52.8 (COOMe), 30.9 (CCl $_3$), 25.5, 25.1 (Me). 9: $[\alpha]_D^{20} = -20.7$ (c 0.1); 103.2, 101.7 (C-1 1 , 1 2), 99.3, 99.1 (C α), 81.1 (C-3 2), 77.3 (C-3 1), 76.5 (C-4 1), 75.1 (C-4 2), 73.1 (C-2 1), 72.1 (C-2 2), 70.1 (CH $_2$ Ph), 66.7 (C-5 1), 66.6 (CH $_2$ O), 65.9 (C-5 2), 65.2, 64.9 (C-6 1 , 6 2), 59.8 (OMe), 53.1, 52.9 (COOMe), 40.9 (CH $_2$ N), 29.5, 29.0, 23.1 (CH $_2$), 25.2, 25.4 (Me). 10: $[\alpha]_D^{20} = 260$ (c 0.2, H $_2$ O); NMR $\delta = 105.6$, 105.3 (C-1 1 , 1 2), 104.5, 104.4 (C α), 84.1 (C-3 2), 82.7 (C-3 1), 77.7 (C-4 2), 76.8 (C-4 1 , 5 2), 75.2 (C-5 1), 73.3 (C-2 2), 68.9, 68.6 (C-2 1 , 6 2), 67.1 (C-6 1), 60.9 (OMe), 42.3 (CH $_2$ N), 31.1, 29.3, 25.0 (CH $_2$), 27.5, 27.3 (CH $_3$). 12: $[\alpha]_D^{20} = 72.2$ (c 0.1); NMR $\delta = 4.88$, 4.56 (d, 2H, H-1 2 , 1 3 , J $_{1,2} = 7.1$, 8.0), 4.10 (d, 1H, H-1 1 , J $_{1,2} = 7.6$), 3.83 (s, 6H, OMe), 3.43, 3.38 (s, 6H, COOMe), 1.53, 1.47 (s, 6H, Me); 104.5 (C-1 1), 100.7 (C-1 3), 99.6 (C-1 2), 99.0, 98.9 (C α), 82.4 (C-3 3), 81.5 (C-3), 80.4 (C-4), 77.9 (C-2), 76.5 (C-4), 75.4 (CH $_2$ Ph), 74.7 (CH $_2$ Ph), 74.2 (C-3,5), 73.8 (C-2), 73.4 (CH $_2$ Ph), 72.8 (C-2), 67.5 (C-6), 65.8 (C-5), 65.7 (C-3), 65.3 (C-6), 64.8 (C-6), 58.0 (3 2 -OMe), 57.0 (1 1 -OMe), 52.8 (COOMe), 52.7 (COOMe), 25.5 (Me), 25.3 (Me). 13: $[\alpha]_D^{20} = 58.2$ (c 0.1, H $_2$ O); 84.1 (C-3 3), 82.6 (C-3 2), 81.3 (C-4 1), 78.0, 77.7 (C-3 1 , 5 1), 77.0, 76.9, 76.8 (C-2 1 , 4 2 , 4 3), 75.9 (C-5 2), 75.5 (C-5 3), 68.5, 68.4 (C-2 2 , 2 3), 67.3, 67.2 (C-6 2 , 6 3), 62.8 (1-OMe), 61.3 (3-OMe), 60.1 (C-6 1), 27.3 (Me).